1. Home
  2. ARWR vs GKOS Comparison

ARWR vs GKOS Comparison

Compare ARWR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arrowhead Pharmaceuticals Inc.

ARWR

Arrowhead Pharmaceuticals Inc.

HOLD

Current Price

$88.70

Market Cap

10.2B

Sector

Health Care

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$152.86

Market Cap

8.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARWR
GKOS
Founded
2003
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
8.7B
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
ARWR
GKOS
Price
$88.70
$152.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
12
Target Price
$83.40
$126.92
AVG Volume (30 Days)
2.0M
768.7K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
99.80
N/A
EPS
N/A
N/A
Revenue
$16,142,321.00
$507,442,000.00
Revenue This Year
N/A
$23.32
Revenue Next Year
N/A
$27.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.33
52 Week Low
$15.01
$73.16
52 Week High
$87.83
$161.53

Technical Indicators

Market Signals
Indicator
ARWR
GKOS
Relative Strength Index (RSI) 65.40 61.41
Support Level $70.03 $96.44
Resistance Level N/A N/A
Average True Range (ATR) 4.40 6.07
MACD 0.06 -0.46
Stochastic Oscillator 77.27 64.85

Price Performance

Historical Comparison
ARWR
GKOS

About ARWR Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: